StockNews.com Initiates Coverage on Cutera (NASDAQ:CUTR)

Equities researchers at StockNews.com initiated coverage on shares of Cutera (NASDAQ:CUTR) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Price Performance

Shares of CUTR opened at $0.47 on Tuesday. The firm has a market cap of $9.43 million, a PE ratio of -0.07 and a beta of 1.31. Cutera has a 1 year low of $0.28 and a 1 year high of $3.18. The stock’s fifty day moving average price is $0.39 and its two-hundred day moving average price is $0.71.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.98). The company had revenue of $32.50 million during the quarter, compared to analyst estimates of $32.57 million. During the same quarter in the prior year, the company earned ($2.22) EPS. Sell-side analysts anticipate that Cutera will post -5.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cutera

A hedge fund recently raised its stake in Cutera stock. Squarepoint Ops LLC increased its stake in Cutera, Inc. (NASDAQ:CUTR) by 164.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 113,964 shares of the medical device company’s stock after purchasing an additional 70,870 shares during the quarter. Squarepoint Ops LLC owned about 0.57% of Cutera worth $172,000 at the end of the most recent quarter. 90.70% of the stock is owned by institutional investors and hedge funds.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.